{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sacituzumab tirumotecan"]],"indication":"pretreated locally advanced/metastatic urothelial carcinoma","name":"TroFuse-031","nct_id":"NCT07419295","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trofuse-031-nct07419295. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TroFuse-031","arms":[{"description":"Participants receive 4 mg/kg of sacituzumab tirumotecan every 2 weeks (Q2W) via intravenous (IV) infusion until disease progression or unacceptable toxicity.","label":"Sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"Participants receive paclitaxel 175 mg/m\\^2, docetaxel 75 mg/m\\^2, or vinflunine 320 mg/m\\^2 IV every 3 weeks (Q3W), at the investigator's discretion, until disease progression or unacceptable toxicity.","label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-04-23","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":590,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab tirumotecan","otherNames":["MK-2870","SKB264","sac-TMT"],"type":"BIOLOGICAL"},{"name":"Vinflunine","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Rescue medications for sacituzumab tirumotecan","otherNames":[],"type":"DRUG"},{"name":"Rescue medications for chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-10","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-07-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 40 months"}],"references":[],"start_date":{"date":"2026-04-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","url":"https://clinicaltrials.gov/study/NCT07419295"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trofuse-031-nct07419295"}